Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15561472 | 1.00 | TDP1 (0.49) | TDP1LMNAALDH1A1CASP3TSHR | |
| SCHEMBL4624003 | 1.00 | TDP1 (0.49) | TDP1LMNAALDH1A1CASP3TSHR | |
| SCHEMBL11964484 | 1.00 | TDP1 (0.49) | TDP1LMNAALDH1A1CASP3TSHR | |
| SCHEMBL31688086 | 0.82 | TDP1 (0.50) | TDP1LMNAALDH1A1CASP3TSHR | |
| SCHEMBL4715603 | 0.82 | TDP1 (0.50) | TDP1LMNAALDH1A1CASP3TSHR | |
| SCHEMBL13937944 | 0.81 | TDP1 (0.46) | TDP1LMNAALDH1A1CASP3TSHR | |
| SCHEMBL13937923 | 0.81 | TDP1 (0.46) | TDP1LMNAALDH1A1CASP3TSHR | |
| SCHEMBL18517072 | 0.78 | MEN1 (0.31) | ALDH1A1NPC1KMT2AMAPT | |
| SCHEMBL16558903 | 0.77 | CASP3 (0.46) | TDP1LMNAALDH1A1CASP3TSHR | |
| SCHEMBL1639092 | 0.77 | LMNA (0.49) | TDP1LMNAALDH1A1CASP3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262224-A1 | Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide | SMITHKLINE BEECHAM CORPORATION | 2008-10-23 | — | — | US | claimed |
| EP-1713790-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID (S)-3-METHYL-1- ((4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZ EPAN-4-YLCARBAMOYL-BUTYL)-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005069981-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID {(S)-3-METHYL-1-[(4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZEPAN-4-YLCARBAMOYL]-BUTYL}-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-04 | — | — | WO | claimed |
| WO-2023138612-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | WO | disclosed |
| CN-107735400-B | Cyclic sulfamoyl arylamide derivatives and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-02-02 | — | — | CN | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| WO-2014022752-A1 | MACROCYCLES AS PIM INHIBITORS | AMGEN INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| EP-2673269-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20080262224-A1 | Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide | SMITHKLINE BEECHAM CORPORATION | 2008-10-23 | — | — | US | disclosed |
| EP-1713790-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID (S)-3-METHYL-1- ((4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZ EPAN-4-YLCARBAMOYL-BUTYL)-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005069981-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID {(S)-3-METHYL-1-[(4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZEPAN-4-YLCARBAMOYL]-BUTYL}-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | TDP1 2020/4885LMNA 1066/4885ALDH1A1 1680/4885 |
| US-20080262224-A1 | Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide | ACMSD, CPS1, BCAT2 | TDP1 3389/4885LMNA 2002/4885ALDH1A1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.